2022年，华领医药的多格列艾汀片（商品名“华堂宁”）获批上市，这是全球首个葡萄糖激酶激活剂（GKA）类降糖新药。这一里程碑式的突破，让华堂宁成为中国生物医药产业“由0到1”的标志性案例。 华堂宁的商业化开局很漂亮，MNC（跨国药企）拜耳负责华堂宁在国内的销售工作。值得一提的是，在降糖药上，拜耳的销售团队曾一手打造拜唐苹的“销售神话”，外界原本预期，华堂宁能在拜耳的加持下迅速打开市场。然而，上市...
Source Link2022年，华领医药的多格列艾汀片（商品名“华堂宁”）获批上市，这是全球首个葡萄糖激酶激活剂（GKA）类降糖新药。这一里程碑式的突破，让华堂宁成为中国生物医药产业“由0到1”的标志性案例。 华堂宁的商业化开局很漂亮，MNC（跨国药企）拜耳负责华堂宁在国内的销售工作。值得一提的是，在降糖药上，拜耳的销售团队曾一手打造拜唐苹的“销售神话”，外界原本预期，华堂宁能在拜耳的加持下迅速打开市场。然而，上市...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.